Antibody Conjugation Approach Enhances Breadth and Potency of Neutralization of Anti-HIV-1 Antibodies and CD4-IgG

Monoclonal antibody therapeutics with up to five specificities: Functional enhancement through fusion of target-specific peptides

(2013) David LaFleur et al.   mAbs

Formylbenzene Diazonium Hexafluorophosphate Reagent for Tyrosine-Selective Modification of Proteins and the Introduction of a Bioorthogonal Aldehyde

(2012) Julia Gavrilyuk et al.   BIOCONJUGATE CHEMISTRY

Recent Progress in Small Molecule CCR5 Antagonists as Potential HIV-1 Entry Inhibitors

(2012) Wenwen Chen et al.   CURRENT PHARMACEUTICAL DESIGN

PGV04, an HIV-1 gp120 CD4 Binding Site Antibody, Is Broad and Potent in Neutralization but Does Not Induce Conformational Changes Characteristic of CD4

(2012) Emilia Falkowska et al.   JOURNAL OF VIROLOGY

Recent Advances in the Development of Small-molecule CCR5 Inhibitors for HIV

(2012) Tao Liu et al.   MINI-REVIEWS IN MEDICINAL CHEMISTRY

Engineering the variable region of therapeutic IgG antibodies

(2011) Tomoyuki Igawa et al.   mAbs

Antibody-based protection against HIV infection by vectored immunoprophylaxis

(2011) Alejandro B. Balazs et al.   NATURE

Broad neutralization coverage of HIV by multiple highly potent antibodies

(2011) Laura M. Walker et al.   NATURE

Focused Evolution of HIV-1 Neutralizing Antibodies Revealed by Structures and Deep Sequencing

(2011) X. Wu et al.   SCIENCE

Increasing the Potency and Breadth of an HIV Antibody by Using Structure-Based Rational Design

(2011) R. Diskin et al.   SCIENCE

Sequence and Structural Convergence of Broad and Potent HIV Antibodies That Mimic CD4 Binding

(2011) J. F. Scheid et al.   SCIENCE

Expanding the Concept of Chemically Programmable Antibodies to RNA Aptamers: Chemically Programmed Biotherapeutics

(2010) Ulrich Wuellner et al.   ANGEWANDTE CHEMIE-INTERNATIONAL EDITION

Potent Inhibition of HIV-1 Entry with a Chemically Programmed Antibody Aided by an Efficient Organocatalytic Synthesis

(2010) Julia Gavrilyuk et al.   CHEMBIOCHEM

Treatment of HIV infection with the CCR5 antagonist maraviroc

(2010) Wiete Kromdijk et al.   EXPERT OPINION ON PHARMACOTHERAPY

Ibalizumab: an anti-CD4 monoclonal antibody for the treatment of HIV-1 infection

(2010) C. J. Bruno et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Epitope Mapping of Ibalizumab, a Humanized Anti-CD4 Monoclonal Antibody with Anti-HIV-1 Activity in Infected Patients

(2010) R. Song et al.   JOURNAL OF VIROLOGY

Variable Loop Glycan Dependency of the Broad and Potent HIV-1-Neutralizing Antibodies PG9 and PG16

(2010) Katie J. Doores et al.   JOURNAL OF VIROLOGY

Rational Design of Envelope Identifies Broadly Neutralizing Human Monoclonal Antibodies to HIV-1

(2010) X. Wu et al.   SCIENCE

Increased sensitivity of HIV variants selected by attachment inhibitors to broadly neutralizing antibodies

(2010) Nannan Zhou et al.   VIROLOGY

The Monoclonal CCR5 Antibody PRO-140: The Promise of Once-Weekly HIV Therapy

(2010) Allan R. Tenorio   Current HIV/AIDS Reports

An efficient chemical approach to bispecific antibodies and antibodies of high valency

(2009) Julia I. Gavrilyuk et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

β-Lactam-based approach for the chemical programming of aldolase antibody 38C2

(2009) Julia I. Gavrilyuk et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Vector-mediated gene transfer engenders long-lived neutralizing activity and protection against SIV infection in monkeys

(2009) Philip R Johnson et al.   NATURE MEDICINE

Maraviroc, a CCR5 Coreceptor Antagonist That Blocks Entry of Human Immunodeficiency Virus Type 1

(2009) Joshua S Hunt et al.   PHARMACOTHERAPY

Variants of the Antibody Herceptin That Interact with HER2 and VEGF at the Antigen Binding Site

(2009) J. Bostrom et al.   SCIENCE

Broad and Potent Neutralizing Antibodies from an African Donor Reveal a New HIV-1 Vaccine Target

(2009) L. M. Walker et al.   SCIENCE